Vaxcyte, Inc. $PCVX Shares Acquired by Handelsbanken Fonder AB

Handelsbanken Fonder AB boosted its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 28.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 45,000 shares of the company’s stock after purchasing an additional 10,100 shares during the quarter. Handelsbanken Fonder AB’s holdings in Vaxcyte were worth $1,621,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of PCVX. Westfield Capital Management Co. LP lifted its stake in shares of Vaxcyte by 21.6% during the third quarter. Westfield Capital Management Co. LP now owns 3,732,715 shares of the company’s stock valued at $134,452,000 after buying an additional 663,817 shares during the period. Federated Hermes Inc. grew its stake in Vaxcyte by 6,856.3% in the 3rd quarter. Federated Hermes Inc. now owns 18,156 shares of the company’s stock worth $654,000 after acquiring an additional 17,895 shares during the period. Edgestream Partners L.P. acquired a new position in Vaxcyte in the 2nd quarter valued at $1,610,000. Y Intercept Hong Kong Ltd acquired a new position in Vaxcyte in the 3rd quarter valued at $2,640,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Vaxcyte by 30.6% during the third quarter. JPMorgan Chase & Co. now owns 1,565,036 shares of the company’s stock worth $56,373,000 after purchasing an additional 366,266 shares during the last quarter. 96.78% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Vaxcyte

In other Vaxcyte news, insider Harpreet S. Dhaliwal sold 9,743 shares of the business’s stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $46.69, for a total value of $454,900.67. Following the transaction, the insider owned 23,928 shares in the company, valued at $1,117,198.32. The trade was a 28.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Elvia Cowan sold 11,623 shares of the company’s stock in a transaction dated Tuesday, December 23rd. The shares were sold at an average price of $47.92, for a total transaction of $556,974.16. Following the completion of the transaction, the senior vice president directly owned 14,534 shares of the company’s stock, valued at approximately $696,469.28. The trade was a 44.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 3.10% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

PCVX has been the subject of several research analyst reports. BTIG Research upped their price target on shares of Vaxcyte from $85.00 to $89.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Leerink Partners set a $77.00 price objective on shares of Vaxcyte and gave the company an “outperform” rating in a research note on Wednesday, November 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a report on Friday, January 9th. Guggenheim reiterated a “buy” rating and issued a $116.00 target price on shares of Vaxcyte in a report on Monday, February 2nd. Finally, Needham & Company LLC boosted their price target on Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $94.50.

Vaxcyte Trading Up 0.5%

Shares of Vaxcyte stock opened at $60.13 on Thursday. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $76.61. The stock has a market cap of $8.65 billion, a price-to-earnings ratio of -10.70 and a beta of 1.31. The company has a fifty day moving average price of $52.52 and a 200 day moving average price of $44.62.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($1.80) EPS for the quarter, missing analysts’ consensus estimates of ($1.46) by ($0.34). During the same period in the prior year, the business posted ($1.12) earnings per share. Analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.